243 related articles for article (PubMed ID: 26936398)
1. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.
Tiffen J; Wilson S; Gallagher SJ; Hersey P; Filipp FV
Neoplasia; 2016 Feb; 18(2):121-32. PubMed ID: 26936398
[TBL] [Abstract][Full Text] [Related]
2. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
3. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer.
Maryan N; Statkiewicz M; Mikula M; Goryca K; Paziewska A; Strzałkowska A; Dabrowska M; Bujko M; Ostrowski J
Mol Med Rep; 2015 Jul; 12(1):728-36. PubMed ID: 25695204
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
6. EZH2 as a mediator of treatment resistance in melanoma.
Tiffen JC; Gallagher SJ; Tseng HY; Filipp FV; Fazekas de St. Groth B; Hersey P
Pigment Cell Melanoma Res; 2016 Sep; 29(5):500-7. PubMed ID: 27063195
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
9. Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis.
Wu S; Wu D; Pan Y; Liu H; Shao Z; Wang M
Pathol Res Pract; 2019 Feb; 215(2):292-301. PubMed ID: 30527357
[TBL] [Abstract][Full Text] [Related]
10. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
11. Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation.
Mochizuki D; Misawa Y; Kawasaki H; Imai A; Endo S; Mima M; Yamada S; Nakagawa T; Kanazawa T; Misawa K
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30469511
[TBL] [Abstract][Full Text] [Related]
12. EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains.
Donaldson-Collier MC; Sungalee S; Zufferey M; Tavernari D; Katanayeva N; Battistello E; Mina M; Douglass KM; Rey T; Raynaud F; Manley S; Ciriello G; Oricchio E
Nat Genet; 2019 Mar; 51(3):517-528. PubMed ID: 30692681
[TBL] [Abstract][Full Text] [Related]
13. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
14. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.
Yu H; Ma M; Yan J; Xu L; Yu J; Dai J; Xu T; Tang H; Wu X; Li S; Lian B; Mao L; Chi Z; Cui C; Guo J; Kong Y
J Transl Med; 2017 Dec; 15(1):243. PubMed ID: 29202777
[TBL] [Abstract][Full Text] [Related]
15. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.
Perotti V; Baldassari P; Molla A; Nicolini G; Bersani I; Grazia G; Benigni F; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2019 May; 38(22):4384-4396. PubMed ID: 30710146
[TBL] [Abstract][Full Text] [Related]
16. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.
Cao J; Pontes KC; Heijkants RC; Brouwer NJ; Groenewoud A; Jordanova ES; Marinkovic M; van Duinen S; Teunisse AF; Verdijk RM; Snaar-Jagalska E; Jochemsen AG; Jager MJ
J Pathol; 2018 Aug; 245(4):433-444. PubMed ID: 29732557
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
19. Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations.
Montagnani V; Benelli M; Apollo A; Pescucci C; Licastro D; Urso C; Gerlini G; Borgognoni L; Luzzatto L; Stecca B
Oncotarget; 2016 May; 7(21):30365-78. PubMed ID: 27095580
[TBL] [Abstract][Full Text] [Related]
20. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.
Zingg D; Debbache J; Schaefer SM; Tuncer E; Frommel SC; Cheng P; Arenas-Ramirez N; Haeusel J; Zhang Y; Bonalli M; McCabe MT; Creasy CL; Levesque MP; Boyman O; Santoro R; Shakhova O; Dummer R; Sommer L
Nat Commun; 2015 Jan; 6():6051. PubMed ID: 25609585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
